ArticleCurrent protein & peptide science2026
Comprehensive Analysis of Glycosyltransferase-Related Genes Reveals their Prognostic and Therapeutic Implications in Stomach Adenocarcinoma.
Article in Current protein & peptide science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to investigate the role of glycosyltransferase-related genes (GRGs) in stomach adenocarcinoma (STAD) through bioinformatic analysis and experimental validation, exploring their potential as prognostic and therapeutic biomarkers.
methodsWe utilized datasets from TCGA-STAD and GSE26901 to establish training and validation cohorts. Prognostic gene signatures were constructed using differentially expressed genes and LASSO regression. Pathway associations were explored via Gene Set Enrichment Analysis (GSEA), and correlations with immune cell infiltration and immune checkpoint genes were analyzed using CIBERSORT, ESTIMATE, and TIDE. Drug sensitivity was assessed using Onco- Predict, and GRG expression was confirmed via qRT-PCR.
resultsWe identified 20 GRGs as prognostic indicators in STAD, with 14 showing abnormal expression. A six-gene signature (B3GAT3, FUT2, GALNT15, GLT8D1, MGAT4C, and ST8SIA6) was constructed, demonstrating AUC values of 0.662, 0.702, and 0.711 in TCGASTAD for predicting overall survival at 1, 3, and 5 years, respectively. The risk score was significantly associated with reduced survival and identified as an independent prognostic marker. The GRG profile was found to be correlated with immune cell infiltration, immune checkpoint genes, and drug responsiveness. DISCUSSION: The study highlights the significance of GRGs in STAD prognosis and potential therapeutic applications. The GRG signature shows promise as a predictive biomarker, with implications for personalized medicine. Limitations include modest AUC values and the need for larger, diverse cohorts for validation. Future work should integrate multi-omics data and explore the roles of GRGs in immune modulation and drug sensitivity.
conclusionThe GRG profile serves as a prognostic biomarker for STAD, offering new insights into therapeutic approaches and potential applications in other gastrointestinal cancers.
Indexed as
Identifiers
40814892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.